The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes ...

Biocon Biologics expands diabetes portfolio with US FDA approval of Kirsty, an interchangeable rapid-acting insulin aspart in US: Our Bureau, Bengaluru Wednesday, July 16, 2025, 1 ...

Biocon share price jumped after its subsidiary Biocon Biologics received USFDA approval for Kirsty, a rapid-acting insulin ...

Biocon announced that its subsidiary, Biocon Biologics, has received US Food and Drug Administration (USFDA) approval for Kirsty (Insulin Aspart-xjhz) 100 units/ml, to improve glycemic control in ...

Currently, Kristy is available in the European Union and Canada markets since 2022. The approval is for the fist and only ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...

The report includes historical data from 2023 to 2024 and forecasts until 2033. The insulin pen market in the United States has experienced remarkable growth over the last few years.

The insulin pens market is witnessing significant growth due to the increasing prevalence of diabetes worldwide and the rising preference for advanced, user-friendly insulin delivery systems. Insulin ...

Prescriptions for insulin glargine-yfgn (Semglee) rapidly increased when its status switched from a standard biosimilar to the first interchangeable insulin biosimilar, an economic evaluation found.

South Africa’s public health care system has run out of the human insulin pens that it provides to people with diabetes, as the pharmaceutical industry shifts production priorities to ...